データなし
データなし
Earnings Scheduled For December 19, 2024
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. GAAP EPS of -$2.78 Misses by $0.18